博茨瓦纳乳腺癌辅助内分泌治疗的坚持:观察性队列分析
Arthur T Johnson1,2, Peter Vuylsteke3,4, Taolo Ntloedibe4
1Botswana Baylor Children's Clinical Center of Excellence, Gaborone, Botswana.
Breast care (Basel, Switzerland)
|October 9, 2025
概括
在博茨瓦纳,辅助内分泌治疗中断是常见的,但大多数雌激素阳性乳腺癌患者继续接受治疗. 药物库存经常会中断治疗,影响南非的药物遵守.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 辅助内分泌疗法对于减少雌激素阳性乳腺癌的复发和死亡率至关重要.
- 坚持内分泌治疗对于长期患者的治疗结果至关重要.
- 南非内分泌治疗持久性的数据有限.
研究的目的:
- 评估在非洲南部的辅助内分泌疗法患者持久性程度.
- 在雌激素阳性乳腺癌患者中确定与非持续性相关的因素.
主要方法:
- 在博茨瓦纳确定了一组雌激素受体阳性乳腺癌的女性患者 (>18岁).
- 持续性被定义为持续使用内分泌疗法超过180天.
- 在持久和非持久组之间比较了临床和人口统计数据.
主要成果:
- 在被处方辅助内分泌治疗的91名患者中,有45人 (50%) 经历了中断,但只有8人 (8.8%) 不持久.
- 塔莫西芬 (63%) 和阿纳斯托 (37%) 是主要使用的药物.
- 收入较高与持续性相关;药物不可用是中断的主要原因.
结论:
- 在博茨瓦纳,辅助内分泌疗法的中断是常见的.
- 尽管有中断,乳腺癌患者坚持使用内分泌疗法仍然很高.
- 药物库存是治疗中断的主要驱动因素.
更多相关视频
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
819
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
